Breyanzi – New CAR T-Cell therapy from BMS

Share This Post

July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (USFDA).

CAR-T cell therapy is a sort of immunotherapy that works by altering a person’s T cells to recognize and destroy cancer cells.

CAR T Cell therapy in India Cost and hospitals

Breyanzi, a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (USFDA) (Lisocabtagene maraleucel; liso-cel).

Also read : CAR T-Cell therapy in India

Adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy will be treated with the new CAR T cell therapy. There are several types of LBCL, such as primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, follicular lymphoma grade 3B, and DLBCL not otherwise described, which can also develop from indolent lymphoma.

DLBCL cancer is the most frequent type of non-Hodgkin lymphoma (NHL), and it is an aggressive illness in which 73 percent of patients do not respond to treatment or recur.

Breyanzi, on the other hand, is not recommended for patients with primary central nervous system lymphoma, despite the fact that it is a potentially curative treatment.

Also read: CAR T-Cell therapy in China

Breyanzi, a CAR T cell therapy, will be very important in clinical practice, giving people with relapsed or refractory large B-cell lymphoma the chance for a long-lasting response with a personalized treatment experience, said Samit Hirawat, chief medical officer at Bristol Myers Squibb. Our unwavering commitment to advancing cell therapy research, providing breakthrough medicines, and supporting patients at every step of their treatment journey is reflected in the FDA approval.”

Breyanzi had a 73 percent overall response rate and a 54 percent complete response (CR) rate in the TRANSCEND NHL 001 study, which was the largest pivotal trial in 3L+ LBCL.

BMS’ immunotherapy manufacturing plant in Bothell, Washington, will produce the novel cell treatment.

CAR T-Cell therapy in India is in the clinical trials stage, and hopefully it will be available very soon for commercial use.

 

 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy